Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CDC25B | P30305 | 2/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370537 | 1.00 | NQO1 (0.57) | NQO1CYP1A2CYP2A6MAPTCYP2D6 | |
| SCHEMBL21117323 | 0.90 | CYP1A2 (0.52) | NQO1CYP1A2CYP2A6MAPTCYP2D6 | |
| SCHEMBL7857849 | 0.90 | NQO1 (0.55) | NQO1CYP1A2CYP2A6MAPTCYP2D6 | |
| SCHEMBL29861922 | 0.86 | NQO1 (0.61) | NQO1CYP1A2CYP2A6MAPTCYP2D6 | |
| SCHEMBL2764307 | 0.86 | NQO1 (0.61) | NQO1CYP1A2CYP2A6MAPTCYP2D6 | |
| SCHEMBL27996593 | 0.84 | NQO1 (0.59) | NQO1CYP1A2CYP2A6MAPTCYP2D6 | |
| SCHEMBL30064911 | 0.83 | CYP1A2 (0.46) | NQO1CYP1A2CYP2A6MAPTCYP2D6 | |
| SCHEMBL23043825 | 0.82 | CYP1A2 (0.44) | NQO1CYP1A2CYP2A6MAPTCYP2D6 | |
| SCHEMBL30706678 | 0.82 | CYP1A2 (0.44) | NQO1CYP1A2CYP2A6MAPTCYP2D6 | |
| SCHEMBL20315127 | 0.82 | CDC25B (0.46) | NQO1CYP1A2CYP2A6MAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022023027-A1 | NOVEL CHROMIUM-BASED CATALYTIC COMPOSITION AND ASSOCIATED METHOD FOR THE TRIMERISATION OF ETHYLENE TO HEXENE-1 | IFP Energies Nouvelles (FR) | 2022-02-03 | — | — | WO | claimed |
| EP-4188596-B1 | ETHYLENE OLIGOMERISATION PROCESS COMPRISING IN SITU PREPARATION OF THE CATALYTIC COMPOSITION | IFP ENERGIES NOW (FR) | 2024-09-18 | — | — | EP | disclosed |
| CN-116217351-B | Preparation method and application of 4-methoxy-2-naphthol | 阜阳欣奕华制药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118043368-A | Aralkyl resin, diluent for epoxy resin, curable resin composition, photosensitive resin composition, cured product, electronic device, and process for producing aralkyl resin | 中央硝子株式会社 | 2024-05-14 | — | — | CN | disclosed |
| CN-115403451-B | Preparation method and application of 4-methoxy-2-naphthol | 阜阳欣奕华制药科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-115504870-B | Preparation method and application of 4-methoxy-2-naphthol | 阜阳欣奕华制药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-115504866-B | Preparation method and application of 4-methoxy-2-naphthol | 阜阳欣奕华制药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-115433062-B | Preparation method and application of 4-methoxy-2-naphthol | 阜阳欣奕华制药科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230271898-A1 | ETHYLENE OLIGOMERISATION PROCESS COMPRISING IN SITU PREPARATION OF THE CATALYTIC COMPOSITION | IFP Energies Nouvelles (FR) | 2023-08-31 | — | — | US | disclosed |
| EP-0356247-A1 | Analgesic carboxylic acid amide derivatives | Sankyo Company Limited (JP) | 1990-02-28 | — | — | EP | disclosed |
| US-4804679-A | INHIBIT CHOLESTEROL BIOSYNTHESIS | SANDOZ PHARM. CORP. (US) | 1989-02-14 | — | — | US | disclosed |
| US-4686237-A | LOWERING BLOOD CHOLESTEROL LEVEL | SANDOZ PHARMACEUTICALS CORP. (US) | 1987-08-11 | — | — | US | disclosed |
| EP-0117228-B1 | ANALOGS OF MEVALONOLACTONE AND DERIVATIVES THEREOF, PROCESSES FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS PHARMACEUTICALS | SANDOZ AG (CH) | 1986-11-05 | — | — | EP | disclosed |
| EP-0117228-A1 | Analogs of mevalonolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals | SANDOZ AG (CH) | 1984-08-29 | — | — | EP | disclosed |
| WO-1984002903-A1 | MEVALONOLACTONE ANALOGS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | SANDOZ AG (CH) | 1984-08-02 | — | — | WO | disclosed |
| US-4229274-A | PHOTOINITIATOR, PHOTOSENSITIZER, QUENCHER, AND COMPOUNDS CONTAINING ACRYLYLOXY GROUPS | PPG INDUSTRIES, INC. (US) | 1980-10-21 | — | — | US | disclosed |
| US-4154715-A | Polymeric polyblend compositions toughened by addition of liquid polymers of a conjugated diene monomer | MONSANTO COMPANY (US) | 1979-05-15 | — | — | US | disclosed |
| US-4049732-A | Continuous telomerization process and its liquid products | LITHIUM CORPORATION OF AMERICA (US) | 1977-09-20 | — | — | US | disclosed |
| US-4041088-A | Recirculation telomerization process and its liquid telomers and liquid telomers produced thereby | LITHIUM CORPORATION OF AMERICA (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | NQO1 480/4885CYP1A2 4527/4885CYP2A6 3249/4885 |
| US-20230271898-A1 | ETHYLENE OLIGOMERISATION PROCESS COMPRISING IN SITU PREPARATION OF THE CATALYTIC COMPOSITION | GALE, EXOC4, EXOC1 | NQO1 2439/4885CYP1A2 582/4885CYP2A6 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.